ARWR Relative Valuation
ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARWR is overvalued; if below, it's undervalued.
Historical Valuation
Arrowhead Pharmaceuticals Inc (ARWR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -26.84. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：64.66
Fair
-20.44
PE
1Y
3Y
5Y
Trailing
Forward
-33.69
EV/EBITDA
Arrowhead Pharmaceuticals Inc. (ARWR) has a current EV/EBITDA of -33.69. The 5-year average EV/EBITDA is -29.86. The thresholds are as follows: Strongly Undervalued below -100.42, Undervalued between -100.42 and -65.14, Fairly Valued between 5.41 and -65.14, Overvalued between 5.41 and 40.69, and Strongly Overvalued above 40.69. The current Forward EV/EBITDA of -33.69 falls within the Historic Trend Line -Fairly Valued range.
-21.15
EV/EBIT
Arrowhead Pharmaceuticals Inc. (ARWR) has a current EV/EBIT of -21.15. The 5-year average EV/EBIT is -23.88. The thresholds are as follows: Strongly Undervalued below -76.82, Undervalued between -76.82 and -50.35, Fairly Valued between 2.59 and -50.35, Overvalued between 2.59 and 29.06, and Strongly Overvalued above 29.06. The current Forward EV/EBIT of -21.15 falls within the Historic Trend Line -Fairly Valued range.
22.10
PS
Arrowhead Pharmaceuticals Inc. (ARWR) has a current PS of 22.10. The 5-year average PS is 24.46. The thresholds are as follows: Strongly Undervalued below -3.24, Undervalued between -3.24 and 10.61, Fairly Valued between 38.30 and 10.61, Overvalued between 38.30 and 52.15, and Strongly Overvalued above 52.15. The current Forward PS of 22.10 falls within the Historic Trend Line -Fairly Valued range.
-42.08
P/OCF
Arrowhead Pharmaceuticals Inc. (ARWR) has a current P/OCF of -42.08. The 5-year average P/OCF is -24.63. The thresholds are as follows: Strongly Undervalued below -156.21, Undervalued between -156.21 and -90.42, Fairly Valued between 41.16 and -90.42, Overvalued between 41.16 and 106.95, and Strongly Overvalued above 106.95. The current Forward P/OCF of -42.08 falls within the Historic Trend Line -Fairly Valued range.
-38.43
P/FCF
Arrowhead Pharmaceuticals Inc. (ARWR) has a current P/FCF of -38.43. The 5-year average P/FCF is 1.51. The thresholds are as follows: Strongly Undervalued below -55.10, Undervalued between -55.10 and -26.80, Fairly Valued between 29.82 and -26.80, Overvalued between 29.82 and 58.13, and Strongly Overvalued above 58.13. The current Forward P/FCF of -38.43 falls within the Undervalued range.
Arrowhead Pharmaceuticals Inc (ARWR) has a current Price-to-Book (P/B) ratio of 18.83. Compared to its 3-year average P/B ratio of 11.84 , the current P/B ratio is approximately 59.06% higher. Relative to its 5-year average P/B ratio of 12.67, the current P/B ratio is about 48.63% higher. Arrowhead Pharmaceuticals Inc (ARWR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -11.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.17% , the current FCF yield is about -100.00% lower.
18.83
P/B
Median3y
11.84
Median5y
12.67
1.78
FCF Yield
Median3y
-11.88
Median5y
-7.17
Competitors Valuation Multiple
The average P/S ratio for ARWR's competitors is , providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ARWR increased by 243.94% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 256.47M.
The secondary factor is the Margin Expansion, contributed -100.04%to the performance.
Overall, the performance of ARWR in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Arrowhead Pharmaceuticals Inc (ARWR) currently overvalued or undervalued?
What is Arrowhead Pharmaceuticals Inc (ARWR) fair value?
How does ARWR's valuation metrics compare to the industry average?
What is the current P/B ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Dec 05 2025?
What is the current FCF Yield for Arrowhead Pharmaceuticals Inc (ARWR) as of Dec 05 2025?
What is the current Forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Dec 05 2025?